• 1
    National Cancer Institute. The U.S. National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) Program (2002): a National Cancer Institute training module. Staging defined. Available at URL: http://training.seer. [accessed November 24, 2004].
  • 2
    FlemingID, CooperJS, HensonDE, et al., editors. AJCC cancer staging manual, 5th ed. Philadelphia: Lippincott-Raven, 1998.
  • 3
    Young JL Jr., Roffers SD, Ries LAG, Fritz AG, Hurlbt AA. SEER summary staging manual—2000: codes and coding instructions. NIH Publ. No. 01-4969. Bethesda: National Cancer Institute, 2001.
  • 4
    Partin AW, Katta MW, Subon MS, et al. Combination of prostate-specific antigen, clinical stage and Gleason score to predict pathological stage of localized prostate cancer: a multi-institutional update. JAMA. 1999; 277: 14451451.
  • 5
    Graefen M, Karakiewicz PI, Cagiannos I, et al. International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2002; 15: 32063212.
  • 6
    National Comprehensive Cancer Network (NCCN). Prostate cancer treatment guidelines for patients. J Natl Compr Canc Netw. 2004; 2: 224248.
  • 7
    Newcomer LM, Stanford JL, Blumenstein BA, et al. Temporal trends in rates of prostate cancer: declining incidence of advanced stage disease, 1974 to 1994. J Urol. 1997; 158: 14271430.
  • 8
    Hankey BF, Feuer EJ, Clegg LX, et al. Cancer surveillance series: interpreting trends in prostate cancer—part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. J Natl Cancer Inst. 1999; 91: 10171024.
  • 9
    Brundrick WS, Culkin DJ, Mata JA, et al. Evaluation of the current incidence of nodal metastasis from prostate cancer. J Surg Oncol. 1993; 52: 269271.
  • 10
    Krongrad A, Lai H, Lai S. Survival after radical prostatectomy. JAMA. 1997; 278: 4450.
  • 11
    Mettlin CJ, Murphy GP, Ho R, Menck HR. The National Cancer Data Base report on longitudinal observations on prostate cancer. Cancer. 1996; 77: 21622166.
  • 12
    Cheng L, Zincke H, Blute ML, et al. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer. 2001; 91: 6673.
  • 13
    Seay TM, Blute ML, Zincke H. Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation. J Urol. 1998; 159: 357364.
  • 14
    Cheng L, Bergstralh EJ, Cheville JC, et al. Cancer volume of lymph node metastasis predicts progression in prostate cancer. Am J Surg Pathol. 1998; 22: 14911500.
  • 15
    Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymph adenectomy in men with node positive prostate cancer. N Engl J Med. 1999; 341: 17811788.
  • 16
    Zagars GK, Pollack A, von Eshenbach AC. Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer. Urology. 2001; 58: 233223.